FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Burning Rock Biotech's FCF Yield % or its related term are showing as below:
FRA:6BU0'
s FCF Yield % Range Over the Past 10 Years
Min: -59.29 Med: -12.89 Max: -0.15
Current: -4.85
During the past 9 years, the highest FCF Yield % of Burning Rock Biotech was -0.15%. The lowest was -59.29%. And the median was -12.89%.
FRA:6BU0's FCF Yield % is ranked worse than 59.81% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.425
vs FRA:6BU0: -4.85
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Burning Rock Biotech FCF Yield % Related Terms
Burning Rock Biotech FCF Yield % Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs XGN, IDXG, PRPO: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a FCF Yield % of -4.85 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #128 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 59.8%.
Is Burning Rock Biotech's FCF Yield % too high?
Burning Rock Biotech's current FCF Yield % is -4.85. Based on the distribution chart, Burning Rock Biotech ranks #128 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's FCF Yield % compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #128 out of 214 companies for FCF Yield %. This places Burning Rock Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current FCF Yield % is -4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Overvalued. The stock's GF Value™ is €6.23, compared to a current price of €7.90 — trading 26.8% above its estimated fair value. The current FCF Yield % is -4.85. Burning Rock Biotech's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current FCF Yield % is -4.85 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €7.90 is trading 26.8% above its estimated GF Value™ of €6.23.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for FRA:6BU0:
FCF Yield %: -4.85
GF Value™: €6.23 vs. price of €7.90 (26.8% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
54GF Score
Get the complete analysis for FRA:6BU0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
